Rituximab-induced Hypogammaglobinemia in Children with Nephrotic Syndrome: A Systematic Review and Meta-Analysis
Jason Chung(University of Toronto), Rahul Chanchlani(McMaster Children's Hospital), Cal Robinson(Hospital for Sick Children), Rajiv Sinha(Institute of Child Health), Arvind Bagga(All India Institute of Medical Sciences), Yuanxin Xue(McMaster University), Joycelyne Ewusie(St. Joseph’s Healthcare Hamilton), Zinnia Chung(McMaster University), Andrew Yu(University of Alberta)
Cited by 0
Related Papers
Patients with Mutations in NPHS2 (Podocin) Do Not Respond to Standard Steroid Treatment of Nephrotic Syndrome
|Journal of the American Society of Nephrology|2004|415
Clinical Features of Anti-Factor H Autoantibody–Associated Hemolytic Uremic Syndrome
|Journal of the American Society of Nephrology|2010|296
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|256
Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children
|Kidney International|2013|216
Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome
|Clinical Journal of the American Society of Nephrology|2010|203